Abstract:To determine the role of hepatitis C virus (HCV) genotype 1 b genetic variation in the open reading frame for treatment outcomes of the pegylated-interferon/ribavirin (peg-IFN/RBV) combination therapy by examining patients from Henan Province with chronic hepatitis C (CHC).Thirty-seven treatment naive patients infected with HCV genotype 1b were included in the study. Prior to initiation of a 48-week course of peg-IFN/RBV therapy, peripheral blood was drawn for sequencing of the viral ORF 5'-half. Patients were assessed at the end of the 48 weeks of treatment and at a 6-month follow-up appointment. The patient data was stratified according to the status of sustained viral response (SVR) group and non-response (NR) and statistical analysis was performed to determine the correlation between detected genetic variations and treatment response status.Genetic variability in the ORF 5'-half was significantly higher among the individuals in the SVR group than among those of the NR group. Significant differences were found in the gene regions encoding p7, NS2 and NS3. For p7, the NR group had actual and expected frequencies of special mutation of 9.0 and 17.4 and total mutation of 77.0 and 68.6, while the SVR group had actual and expected frequencies of special mutation of 42.0 and 33.6 and total mutation of 124.0 and 132.4 (x2 =7.725, P =0.05). For NS2, the NR group had actual and expected frequencies of special mutation of 36.0 and 54.3 and total mutation of 270.0 and 251.7, while the SVR group had actual and expected frequencies of special mutation of 106.0 and 87.7 and total mutation of 388.0 and 406.3 (x2 = 12.16, P less than 0.01). For NS3, the NR group had actual and expected frequencies of special mutation of 49.0 and 53.4 and total mutation of 241.0 and 236.6, while the SVR group had actual and expected frequencies of special mutation of 81.0 and 76.6 and total mutation of 335.0 and 339.4 (x2 =6.745, P =0.043). The inter-patient genetic variations in the NS3 gene were concentrated in the protease domain. Furthermore, there was a strong correlation between HCV diversity in p7 and treatment outcome.The genetic data reported here provides strong support for the role of NS2, NS3 and p7 in antagonizing the peg-IFN/RBV response during the treatment of HCV infections. We conclude that higher inter-patient viral genetic diversity correlates with successful treatment and may modulate the efficacy of antiviral therapy in CHC patients of Henan.

Interaction Between Variability of Nonstructural Gene5b of Hepatitis C Virus and Interferon Therapy

[Variation in Hepatitis C Virus NS 5b Nucleotide Sequence and Its Relationship with Interferon Treatment].

A Functional SNP of Interferon-Γ Gene is Important for Interferon-Α-induced and Spontaneous Recovery from Hepatitis C Virus Infection

Evolution of viral RNA in a Chinese patient to interferon/ribavirin therapy for hepatitis C

Association of Single Nucleotide Polymorphisms in Interferon Signaling Pathway Genes and Interferon-Stimulated Genes with the Response to Interferon Therapy for Chronic Hepatitis C

Association Between NS5A Gene Sequence and Response to Interferon Therapy in Chronic Hepatitis C Patients in Shanghai

What are the limits of efficacy for immunotherapy against hepatocellular carcinoma and its clinical availability

Mutations in the NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated interferon alpha-2a and ribavirin combination therapy

Sequence Diversity of Hepatitis C Virus 6a Within the Extended Interferon Sensitivity-Determining Region Correlates with Interferon-Alpha/ribavirin Treatment Outcomes

Nonstructural 5A gene variability of hepatitis C virus (HCV) during a 10-year follow up

Amino Acid Sequence Analysis in Patients with Chronic HCV Genotype 1b Infection During Pegylated Interferon-Α2a and Ribavirin Therapy.

Study on the HCV Gene Mutation in Lanzhou and the Relationship with Interferon-Α Induced Immune Response

HCV Genotype,Serum HCV RNA Load,Liver Lesion and Efficacy of α- Interferon on Patients with Chronic Hepatitis C

Gene Heterogeneity of Hepatitis B Virus Isolates from Patients with Severe Hepatitis B.

Interferon lambda 4 impacts the genetic diversity of hepatitis C virus

Analysis of Hepatitis B Virus Genotypes and Pre-Core Region Variability During Interferon Treatment of HBe Antigen Negative Chronic Hepatitis B.

Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy

Evaluation of Susceptibility Locus for Response to Interferon-Α Based Therapy in Chronic Hepatitis B Patients in Chinese

Genetic Variability and Characterization of Non-Structural Region 5 of Hepatitis C Virus Genome from Chinese Patients

Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients.

IFIT1 Polymorphisms Predict Interferon-Α Treatment Efficiency for Hepatitis B Virus Infection.